Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Alemtuzumab-induced remission of multiple sclerosis-associated uveitis

Willis, Mark, Pickersgill, Trevor, Robertson, Neil, Lee, Richard W. J., Dick, Andrew D. and Carreño, Ester 2016. Alemtuzumab-induced remission of multiple sclerosis-associated uveitis. International Ophthalmology 10.1007/s10792-016-0370-9

[img]
Preview
PDF - Accepted Post-Print Version
Download (288kB) | Preview

Abstract

Purpose The purpose of the study was to report a case of multiple sclerosis (MS)-associated uveitis refractory to conventional immunosuppressants, with subsequent remission following treatment with alemtuzumab. Methods Case report Patient was treated with intravenous alemtuzumab, a lymphocyte depleting anti-CD52 monoclonal antibody that has recently been approved for use in relapsing MS. Results A 17-year-old female presented with bilateral optic neuritis and subsequently bilateral intermediate uveitis and secondary macular oedema. She was diagnosed with active relapsing MS for which she received treatment with alemtuzumab. The intraocular inflammation previously refractory to conventional immunosuppressants responded to alemtuzumab, inducing remission. Conclusions To our knowledge, this is the first such report of alemtuzumab treatment in MS-associated ocular inflammatory disease and may demonstrate a potential utility for this drug in related conditions.

Item Type: Article
Date Type: Published Online
Status: Published
Schools: Medicine
MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Subjects: R Medicine > R Medicine (General)
Uncontrolled Keywords: Multiple sclerosisUveitisAlemtuzumabIntraocular inflammation
Publisher: Springer Verlag
ISSN: 0165-5701
Date of First Compliant Deposit: 14 December 2016
Date of Acceptance: 29 September 2016
Last Modified: 12 Oct 2017 15:21
URI: http://orca.cf.ac.uk/id/eprint/96900

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics